Cidara Therapeutics, Inc. - Common Stock, $0.0001 par value per share (CDTX)

Historical Holders from Q2 2024 to Q3 2025

Symbol
CDTX on Nasdaq
Type / Class
Equity / Common Stock, $0.0001 par value per share
Shares outstanding
31,522,645
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
32,486,735
Holdings value
$3,110,319,924
% of all portfolios
0.01%
Number of holders
167
Number of buys
120
Number of sells
-41
Average buys %
+0%
Average sells %
-0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Cidara Therapeutics, Inc. - Common Stock, $0.0001 par value per share (CDTX)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
RA CAPITAL MANAGEMENT, L.P. 10.7% 0% $324,340,276 3,372,923 0% RA Capital Management, L.P. 13 Nov 2025
BCLS Fund III Investments, LP 9.99% 0% $289,290,002 +$49,824,886 3,020,990 +20.8% BCLS Fund III Investments, LP 30 Sep 2025
Point72 Asset Management, L.P. 6.2% -17.5% $151,115,887 +$4,801,311 1,578,069 +3.28% Point72 Asset Management, L.P. 30 Sep 2025
BIOTECHNOLOGY VALUE FUND L P 4.4% -16% $113,871,586 -$21,545,460 1,189,165 -15.9% BVF PARTNERS L P/IL 15 Oct 2025
Vivo Opportunity Fund Holdings, L.P. 4.6% -2% $59,424,730 +$28,480,301 1,175,796 +92% Vivo Opportunity Fund Holdings, L.P. 30 Jun 2025
BlackRock, Inc. 4.6% -15% $111,424,214 +$5,356,584 1,163,607 +5.05% BlackRock, Inc. 30 Sep 2025
Adage Capital Management, L.P. 4.97% -45.2% $55,594,000 +$5,559,400 1,100,000 +11.1% Adage Capital Management, L.P. 30 Jun 2025
Paradigm Biocapital Advisors LP 3.3% -38.3% $92,041,065 -$16,034,916 961,164 -14.8% Paradigm BioCapital Advisors LP 30 Sep 2025
Venrock Healthcare Capital Partners III, L.P. 3.2% -67% $32,299,508 -$23,243,750 639,088 -41.8% Venrock Healthcare Capital Partners III, L.P. 30 Jun 2025
Commodore Capital LP 2% -58.3% $56,019,600 -$56,498,400 585,000 -50.2% Commodore Capital LP 30 Sep 2025

Institutional Holders of Cidara Therapeutics, Inc. - Common Stock, $0.0001 par value per share (CDTX)

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q3 32,486,735 $3,110,319,924 +$679,671,198 $95.76 167
2025 Q2 25,911,048 $1,262,611,204 +$803,273,260 $48.71 106
2025 Q1 9,559,359 $205,909,478 +$57,592,846 $21.54 45
2024 Q4 6,873,669 $183,637,032 +$100,865,295 $26.88 40
2024 Q3 3,308,428 $35,565,026 +$20,361,776 $10.75 27
2024 Q2 1,412,361 $16,863,937 +$16,863,734 $11.94 25